Whitehead Warren 4

4 · Aptose Biosciences Inc. · Filed Jun 25, 2020

Insider Transaction Report

Form 4

Period: 2020-06-23

Aptose Biosciences Inc.APTO

Whitehead Warren

Director

Transactions

Exercise/Conversion
Common Shares
2020-06-24$2.60/sh+7,000$18,200→ 57,000 total
Sale
Common Shares
2020-06-24$6.73/sh−12,000$80,760→ 45,000 total
Exercise/Conversion
Common Shares
2020-06-23$1.60/sh+500$800→ 51,750 total
Exercise/Conversion
Common Shares
2020-06-23$1.12/sh+10,000$11,200→ 63,000 total
Exercise/Conversion
Director Stock Option (Right to Buy)
2020-06-23+500→ 0 total
Exercise: $1.60From: 2012-03-09Exp: 2022-03-09→ Common Shares (500 underlying)
Exercise/Conversion
Director Stock Option (Right to Buy)
2020-06-23+1,250→ 0 total
Exercise: $4.22From: 2011-11-29Exp: 2021-11-29→ Common Shares (1,250 underlying)
Exercise/Conversion
Director Stock Option (Right to Buy)
2020-06-24+5,000→ 0 total
Exercise: $1.02From: 2017-06-06Exp: 2027-06-06→ Common Shares (5,000 underlying)
Exercise/Conversion
Common Shares
2020-06-24$1.02/sh+5,000$5,100→ 50,000 total
Exercise/Conversion
Director Stock Option (Right to Buy)
2020-06-23+10,000→ 0 total
Exercise: $1.12From: 2017-03-28Exp: 2027-03-28→ Common Shares (10,000 underlying)
Sale
Common Shares
2020-06-24$6.78/sh−5,000$33,900→ 40,000 total
Exercise/Conversion
Director Stock Option (Right to Buy)
2020-06-23+1,250→ 0 total
Exercise: $1.91From: 2011-11-29Exp: 2021-11-29→ Common Shares (1,250 underlying)
Exercise/Conversion
Director Stock Option (Right to Buy)
2020-06-24+7,000→ 53,000 total
Exercise: $2.60From: 2018-01-19Exp: 2028-01-19→ Common Shares (7,000 underlying)
Exercise/Conversion
Common Shares
2020-06-23$1.91/sh+1,250$2,388→ 51,250 total
Exercise/Conversion
Common Shares
2020-06-23$4.22/sh+1,250$5,275→ 53,000 total
Sale
Common Shares
2020-06-23$7.08/sh−13,000$92,040→ 50,000 total
Sale
Common Shares
2020-06-23$7.17/sh−5,000$35,850→ 45,000 total

Footnotes (10)

[F1]Converted from Canadian exercise price of $2.58 using an exchange rate of 1.3516.
[F10]Converted from Canadian sales price of $9.1678 using an exchange rate of 1.3516.
[F2]Converted from Canadian exercise price of $2.16 using an exchange rate of 1.3516.
[F3]Converted from Canadian exercise price of $5.70 using an exchange rate of 1.3516.
[F4]Converted from Canadian exercise price of $1.52 using an exchange rate of 1.3516.
[F5]Converted from Canadian exercise price of $1.38 using an exchange rate of 1.3516.
[F6]Converted from Canadian exercise price of $3.52 using an exchange rate of 1.3516.
[F7]The sale price of $7.08 is a weighted average price. These shares were sold in multiple transactions at prices ranging from C$9.55 to C$9.6464, inclusive. The reporting person undertakes to provide to Aptose Biosciences Inc., any security holder of Aptose Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the rages set forth in this footnote (7). The average weighted sale price of C$9.57 was converted into U.S. dollars using an exchange rate of 1.3516.
[F8]Converted from Canadian sale price of $9.69 using an exchange rate of 1.3516.
[F9]The sale price of $6.73 is a weighted average price. These shares were sold in multiple transactions at prices ranging from C$9.00 to C$9.22, inclusive. The reporting person undertakes to provide to Aptose Biosciences Inc., any security holder of Aptose Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the rages set forth in this footnote (9). The Canadian average weighted sale price of $9.09 was converted to U.S. dollars using an exchange rate of 1.3516.

Documents

1 file

4
doc1.xmlPrimary
FORM 4